Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

(2020) Charles M. Rudin et al.   JOURNAL OF CLINICAL ONCOLOGY

A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab

(2019) Andrea Botticelli et al.   Journal of Translational Medicine

A Randomized Non-Comparative Phase 2 Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients with Small Cell Lung Cancer: Results from the IFCT-1603 Trial

(2019) Jean-Louis Pujol et al.   Journal of Thoracic Oncology

LBA1_PRNivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study

(2019) T K Owonikoko et al.   ANNALS OF ONCOLOGY

Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell Carcinoma

(2019) SUGURU SHIROTAKE et al.   ANTICANCER RESEARCH

Blood Predictive Biomarkers for Patients With Non–small-cell Lung Cancer Associated With Clinical Response to Nivolumab

(2019) M. Teresa Agulló-Ortuño et al.   Clinical Lung Cancer

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

(2019) Neal E. Ready et al.   Journal of Thoracic Oncology

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

(2019) Hyun Cheol Chung et al.   Journal of Thoracic Oncology

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

(2018) E E Vokes et al.   ANNALS OF ONCOLOGY

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

(2018) Karina Kulangara et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

(2018) Matthew D. Hellmann et al.   CANCER CELL

Bigger is not always better: Tumor size and prognosis in advanced melanoma

(2018) Allison Betof Warner et al.   CLINICAL CANCER RESEARCH

Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.

(2018) Hyun Cheol Chung et al.   JOURNAL OF CLINICAL ONCOLOGY

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

(2018) Neal Ready et al.   Journal of Thoracic Oncology

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma

(2016) S Diem et al.   BRITISH JOURNAL OF CANCER

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

(2016) Scott J Antonia et al.   LANCET ONCOLOGY

Prognostic effect of liver metastasis in lung cancer patients with distant metastasis

(2016) Yijiu Ren et al.   Oncotarget

Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer

(2014) Joachim von Pawel et al.   JOURNAL OF CLINICAL ONCOLOGY

Relapsed small cell lung cancer: treatment options and latest developments

(2014) Nobuhiro Asai et al.   Therapeutic Advances in Medical Oncology

Specific organ metastases and survival in small cell lung cancer

(2012) KENSUKE NAKAZAWA et al.   Oncology Letters

Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer – A retrospective single institution analysis

(2010) Andreas Hermes et al.   RESPIRATORY MEDICINE

New Advances in the Second-Line Treatment of Small Cell Lung Cancer

(2009) J. L. Hurwitz et al.   ONCOLOGIST

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER